0001950047-24-002811.txt : 20240401 0001950047-24-002811.hdr.sgml : 20240401 20240401163509 ACCESSION NUMBER: 0001950047-24-002811 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240401 DATE AS OF CHANGE: 20240401 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 24810019 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: Krognes Steve E. CENTRAL INDEX KEY: 0001666236 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 144 MAIL ADDRESS: STREET 1: 863 MITTEN ROAD, SUITE 102 CITY: BURLINGAME STATE: CA ZIP: 94010 144 1 primary_doc.xml 144 0001666236 XXXXXXXX LIVE 0001714899 DENALI THERAPEUTICS INC 001-38311 161 Oyster Point Blvd. South San Francisco CA 94080 6508668548 STEVE EDWARD KROGNES Director Common Morgan Stanley Smith Barney LLC Executive Financial Services

1 New York Plaza 8th Floor New York NY 10004

92500 1898100.00 139160239 04/01/2024 NASDAQ Common 08/20/2019 Restricted Stock Units Issuer N 30000 08/20/2019 N/A Common 07/19/2022 Previously Exercised Stock Options Issuer N 62500 07/19/2022 Cash Y The securities to be sold were acquired upon the vesting of restricted stock units during the period of 8/20/2019 through 8/18/2023 04/01/2024 12/01/2023 /s/ Steve Krognes